Newly synthesized human delta opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome
- PMID: 11054417
- DOI: 10.1074/jbc.M007151200
Newly synthesized human delta opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome
Abstract
We have previously shown that only a fraction of the newly synthesized human delta opioid receptors is able to leave the endoplasmic reticulum (ER) and reach the cell surface (Petäjä-Repo, U. E, Hogue, M., Laperrière, A., Walker, P., and Bouvier, M. (2000) J. Biol. Chem. 275, 13727-13736). In the present study, we investigated the fate of those receptors that are retained intracellularly. Pulse-chase experiments revealed that the disappearance of the receptor precursor form (M(r) 45,000) and of two smaller species (M(r) 42,000 and 39,000) is inhibited by the proteasome blocker, lactacystin. The treatment also promoted accumulation of the mature receptor form (M(r) 55,000), indicating that the ER quality control actively routes a significant proportion of rescuable receptors for proteasome degradation. In addition, degradation intermediates that included full-length deglycosylated (M(r) 39,000) and ubiquitinated forms of the receptor were found to accumulate in the cytosol upon inhibition of proteasome function. Finally, coimmunoprecipitation experiments with the beta-subunit of the Sec61 translocon complex revealed that the receptor precursor and its deglycosylated degradation intermediates interact with the translocon. Taken together, these results support a model in which misfolded or incompletely folded receptors are transported to the cytoplasmic side of the ER membrane via the Sec61 translocon, deglycosylated and conjugated with ubiquitin prior to degradation by the cytoplasmic 26 S proteasomes.
Similar articles
-
The mechanism underlying cystic fibrosis transmembrane conductance regulator transport from the endoplasmic reticulum to the proteasome includes Sec61beta and a cytosolic, deglycosylated intermediary.J Biol Chem. 1998 Nov 6;273(45):29873-8. doi: 10.1074/jbc.273.45.29873. J Biol Chem. 1998. PMID: 9792704
-
Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum.J Biol Chem. 1998 Oct 16;273(42):27225-30. doi: 10.1074/jbc.273.42.27225. J Biol Chem. 1998. PMID: 9765244
-
Endoplasmic reticulum degradation of a mutated ATP-binding cassette transporter Pdr5 proceeds in a concerted action of Sec61 and the proteasome.J Biol Chem. 1998 Dec 4;273(49):32848-56. doi: 10.1074/jbc.273.49.32848. J Biol Chem. 1998. PMID: 9830032
-
Endoplasmic reticulum-associated protein degradation.Semin Cell Dev Biol. 2000 Jun;11(3):159-64. doi: 10.1006/scdb.2000.0160. Semin Cell Dev Biol. 2000. PMID: 10906272 Review.
-
Endoplasmic reticulum degradation: reverse protein flow of no return.FASEB J. 1997 Dec;11(14):1227-33. doi: 10.1096/fasebj.11.14.9409541. FASEB J. 1997. PMID: 9409541 Review.
Cited by
-
CRF binding protein facilitates the presence of CRF type 2α receptor on the cell surface.Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):4075-80. doi: 10.1073/pnas.1523745113. Epub 2016 Mar 28. Proc Natl Acad Sci U S A. 2016. PMID: 27035969 Free PMC article.
-
Novel, gel-free proteomics approach identifies RNF5 and JAMP as modulators of GPCR stability.Mol Endocrinol. 2013 Aug;27(8):1245-66. doi: 10.1210/me.2013-1091. Epub 2013 Jun 24. Mol Endocrinol. 2013. PMID: 23798571 Free PMC article.
-
Ubiquitination of G protein-coupled receptors: functional implications and drug discovery.Mol Pharmacol. 2012 Oct;82(4):563-70. doi: 10.1124/mol.112.079418. Epub 2012 Jun 14. Mol Pharmacol. 2012. PMID: 22700696 Free PMC article. Review.
-
Melanocortin-2 receptor accessory protein MRAP forms antiparallel homodimers.Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20244-9. doi: 10.1073/pnas.0708916105. Epub 2007 Dec 12. Proc Natl Acad Sci U S A. 2007. PMID: 18077336 Free PMC article.
-
Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor.PLoS One. 2013 Jun 10;8(6):e65767. doi: 10.1371/journal.pone.0065767. Print 2013. PLoS One. 2013. PMID: 23762421 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources